Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia
Publication
, Conference
Zeidan, AM; Fathi, AT; Issa, GC; Erba, HP; Ahsan, J; Corum, D; Tomkinson, BE; Kozlek, T; Leoni, M; Wang, ES
Published in: JOURNAL OF CLINICAL ONCOLOGY
2023
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Zeidan, A. M., Fathi, A. T., Issa, G. C., Erba, H. P., Ahsan, J., Corum, D., … Wang, E. S. (2023). Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 41).
Zeidan, Amer Methqal, Amir Tahmasb Fathi, Ghayas C. Issa, Harry Paul Erba, Julie Ahsan, Daniel Corum, Blake E. Tomkinson, Tom Kozlek, Mollie Leoni, and Eunice S. Wang. “Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 41, 2023.
Zeidan AM, Fathi AT, Issa GC, Erba HP, Ahsan J, Corum D, et al. Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia. In: JOURNAL OF CLINICAL ONCOLOGY. 2023.
Zeidan, Amer Methqal, et al. “Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia.” JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 16, 2023.
Zeidan AM, Fathi AT, Issa GC, Erba HP, Ahsan J, Corum D, Tomkinson BE, Kozlek T, Leoni M, Wang ES. Phase 1 study of ziftomenib (KO-539) in combination with venetoclax or venetoclax/azacitidine or standard induction cytarabine/daunorubicin (7+3) chemotherapy for the treatment of patients with acute myeloid leukemia. JOURNAL OF CLINICAL ONCOLOGY. 2023.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2023
Volume
41
Issue
16
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences